Different Doses of Rosuvastatin Therapy on Regression of Critical Coronary Atherosclerosis in ACS Patients
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Rosuvastatin 10mg/d or 20mg/d for 36 weeks
can regress critical coronary atherosclerosis as determined by IVUS imaging in Chinese Acute
Coronary Syndrome (ACS) patients.